Genesis Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Genesis Therapeutics (now Genesis Molecular AI) is a biotech company applying AI to small molecule drug discovery; raised $200M Series B in 2025 led by Andreessen Horowitz, Fidelity, BlackRock, and NVIDIA;
About
Genesis Therapeutics — now operating as Genesis Molecular AI — is a clinical-stage biotechnology company founded in 2019 and headquartered in Burlingame, California. The company applies artificial intelligence and machine learning to the discovery and optimization of small molecule drug candidates, with a focus on targets that have historically been considered intractable or undruggable by conventional computational chemistry approaches. Its proprietary platform, GEMS (Genesis Exploration of Molecular Space), uses deep learning to navigate the vast chemical space of possible drug-like molecules, identifying novel compounds with high predicted potency, selectivity, and drug-like properties against disease-relevant protein targets.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.